Capricor Therapeutics (NASDAQ:CAPR) Cut to Neutral at Cantor Fitzgerald

Cantor Fitzgerald cut shares of Capricor Therapeutics (NASDAQ:CAPR) from an overweight rating to a neutral rating in a research report released on Thursday morning, Marketbeat Ratings reports. Cantor Fitzgerald currently has $3.50 target price on the biotechnology company’s stock.

A number of other analysts have also commented on the company. Piper Sandler lowered Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $2.00 price objective for the company. in a report on Thursday. HC Wainwright restated a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Oppenheimer reiterated a “market perform” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Finally, Roth Capital lowered Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price target for the company. in a research report on Monday, July 27th. Ten research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $29.15.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR opened at $3.85 on Thursday. The stock has a market capitalization of $222.95 million, a P/E ratio of -1.66 and a beta of 0.42. The company has a 50-day moving average price of $23.00 and a 200-day moving average price of $26.77. Capricor Therapeutics has a 1 year low of $2.96 and a 1 year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). As a group, equities research analysts anticipate that Capricor Therapeutics will post -1.62 earnings per share for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer owned 11,223 shares in the company, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 25,000 shares of company stock valued at $759,158. Corporate insiders own 9.20% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in shares of Capricor Therapeutics by 122.2% during the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the last quarter. ACT Capital Management LLC purchased a new position in Capricor Therapeutics in the fourth quarter worth $43,000. KBC Group NV bought a new position in Capricor Therapeutics in the 1st quarter valued at $44,000. Tower Research Capital LLC TRC grew its stake in Capricor Therapeutics by 280.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,748 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 4,976 shares during the period. Finally, Regal Investment Advisors LLC bought a new position in Capricor Therapeutics in the 3rd quarter valued at $92,000. 21.68% of the stock is owned by institutional investors.

Key Headlines Impacting Capricor Therapeutics

Here are the key news stories impacting Capricor Therapeutics this week:

• Neutral Sentiment: The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted 9-3 that available evidence did not support Deramiocel’s effectiveness. The vote is non-binding, so the FDA could still reach a different decision, but it is a significant setback for Capricor’s regulatory path. Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel
• Neutral Sentiment: FDA briefing materials and media reports questioned whether Deramiocel met its pre-specified cardiac endpoint and challenged Capricor’s interpretation of Phase 3 results. The dispute centers on changes to the statistical analysis plan that allegedly were not agreed to by the FDA before the company resubmitted its biologics license application. Capricor plummets after FDA panel votes against Duchenne heart disease therapy
• Negative Sentiment: Multiple law firms have announced securities-fraud investigations or filed shareholder class actions alleging that Capricor made materially misleading statements or failed to disclose regulatory and clinical-data risks related to Deramiocel. The lawsuits add legal, financial and reputational risk, although the allegations have not been proven. Investors have been encouraged to contact the firms, with some notices citing a September 28, 2026 deadline. CAPR Investor Alert: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics Investors
• Negative Sentiment: Analysts responded by cutting ratings, including downgrades from Cantor Fitzgerald, Maxim Group, Ladenburg Thalmann and Alliance Global Partners. Cantor moved to Neutral with a $3.50 price target, while JonesTrading reaffirmed a Hold rating. Capricor Therapeutics downgraded by Cantor Fitzgerald

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.